GCC shingles vaccine market report size, share, growth drivers, trends, opportunities & forecast 2025–2030

GCC Shingles Vaccine Market Overview

• The GCC Shingles Vaccine Market is valued at USD 120 million, based on a five-year historical analysis. This estimate is derived from the global shingles vaccine market size of USD 4.8–5.6 billion, with the GCC region representing a small but rapidly growing share due to its population and healthcare investment . Growth is primarily driven by an increasing aging population, rising awareness about shingles and its complications, and the expansion of healthcare infrastructure in the region. The market is further propelled by government-led adult immunization programs, the introduction of recombinant vaccines, and improved cold-chain logistics for vaccine distribution .
• Key players in this market include Saudi Arabia, the UAE, and Qatar. These countries dominate the market due to their advanced healthcare systems, high disposable incomes, and government initiatives promoting vaccination programs. The increasing prevalence of shingles among older adults, coupled with targeted public health campaigns and improved access to recombinant vaccines, further contributes to their market leadership .
• In 2023, the Saudi Arabian government implemented a national vaccination program aimed at increasing the uptake of shingles vaccines among the elderly population. This initiative includes subsidizing vaccine costs and launching public awareness campaigns to educate citizens about the benefits of vaccination, thereby enhancing public health outcomes. The program is governed by the "National Immunization Schedule for Adults," issued by the Saudi Ministry of Health in 2023, which mandates coverage for shingles vaccination among adults aged 50 and above, with compliance monitored through healthcare provider reporting and periodic audits .

GCC Shingles Vaccine Market Segmentation

By Type:The market is segmented into three types of vaccines: Live Attenuated Vaccine, Recombinant Vaccine, and Others. The Live Attenuated Vaccine has historically been widely used due to its effectiveness and established safety profile in preventing shingles. However, the Recombinant Vaccine segment is rapidly gaining traction, driven by its superior efficacy in older adults, longer-lasting immunity, and favorable safety profile. The "Others" category includes alternative formulations and combination vaccines designed for specific patient populations, such as immunocompromised individuals .

By End-User:The end-user segmentation includes Hospitals, Clinics, Pharmacies, and Others. Hospitals are the leading end-users due to their capacity to administer vaccines on a large scale and provide comprehensive healthcare services. Clinics play a significant role, particularly in urban and suburban areas, offering targeted immunization services. Pharmacies are increasingly popular vaccination sites, driven by their accessibility, extended operating hours, and integration into national immunization programs. The "Others" segment includes workplace health centers and mobile vaccination units, which are expanding coverage among high-risk groups .

GCC Shingles Vaccine Market Competitive Landscape

The GCC Shingles Vaccine Market is characterized by a dynamic mix of regional and international players. Leading participants such as GlaxoSmithKline plc., Merck & Co., Inc., Sanofi Pasteur, Pfizer Inc., AstraZeneca plc, Novartis AG, Johnson & Johnson (Janssen Pharmaceuticals), Seqirus (CSL Limited), Bharat Biotech International Limited, Serum Institute of India Pvt. Ltd., Takeda Pharmaceutical Company Limited, BioNTech SE, Moderna, Inc., VBI Vaccines Inc., EpiVax, Inc. contribute to innovation, geographic expansion, and service delivery in this space.

GCC Shingles Vaccine Market Industry Analysis

Growth Drivers

• Increasing Prevalence of Shingles in the Aging Population:The GCC region is witnessing a significant rise in shingles cases, particularly among individuals aged 50 and above. According to the World Health Organization, the incidence of shingles increases with age, with approximately 1 in 3 individuals developing the condition in their lifetime. In future, it is estimated that over 1.8 million people in the GCC will be affected, driving demand for effective vaccination solutions to mitigate this public health concern.
• Rising Awareness About the Benefits of Vaccination:Public health campaigns across the GCC have significantly increased awareness regarding the importance of vaccination against shingles. Reports indicate that vaccination rates have risen by 30% in the last two years, with over 780,000 doses administered in the most recent year alone. This growing awareness is crucial in encouraging the population to seek preventive measures, thereby boosting the shingles vaccine market as more individuals opt for vaccination.
• Government Initiatives Promoting Vaccination Programs:Governments in the GCC are actively promoting vaccination programs to enhance public health. For instance, the Saudi Ministry of Health allocated 187.5 million USD in the most recent year to support vaccination initiatives, including shingles vaccines. Such investments are expected to increase accessibility and affordability, leading to a projected 20% increase in vaccination rates in future, further propelling market growth in the region.

Market Challenges

• High Cost of Shingles Vaccines:The cost of shingles vaccines remains a significant barrier to widespread adoption in the GCC. Prices can range from 200 USD to 300 USD per dose, making it unaffordable for many, especially in lower-income segments. In future, it is estimated that only 25% of the eligible population will be able to afford the vaccine, limiting market penetration and overall vaccination rates in the region.
• Vaccine Hesitancy Among the Population:Vaccine hesitancy poses a considerable challenge to the shingles vaccine market in the GCC. Misinformation and cultural beliefs contribute to reluctance in seeking vaccination. A survey conducted in the most recent year revealed that 40% of respondents expressed concerns about vaccine safety and efficacy. This hesitancy could hinder efforts to achieve higher vaccination rates, impacting market growth and public health outcomes.

GCC Shingles Vaccine Market Future Outlook

The future of the shingles vaccine market in the GCC appears promising, driven by increasing healthcare investments and a growing emphasis on preventive care. As governments enhance healthcare infrastructure, vaccination programs are expected to expand, improving access to vaccines. Additionally, the integration of digital health solutions will facilitate better patient education and outreach, addressing vaccine hesitancy. These trends indicate a robust market environment, fostering innovation and collaboration among stakeholders to enhance vaccination rates and public health outcomes.

Market Opportunities

• Expansion of Healthcare Infrastructure:The GCC is investing heavily in healthcare infrastructure, with over 40 billion USD allocated for development projects in future. This expansion will improve access to vaccination services, particularly in underserved areas, creating a favorable environment for shingles vaccine uptake and market growth.
• Collaborations with Private Healthcare Providers:Partnerships between public health authorities and private healthcare providers are on the rise, with over 60 collaborations established in the most recent year. These alliances aim to enhance vaccine distribution and administration, providing a significant opportunity to increase vaccination rates and improve public health outcomes in the GCC.